

Giuseppe Curigliano

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8033883/giuseppe-curigliano-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

603
papers

24,562
citations

71
h-index

142
g-index

768
ext. papers

33,123
ext. citations

6.6
avg, IF

7.23
L-index

#	Paper	IF	Citations
603	Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.. <i>Journal of Geriatric Oncology</i> , 2022 ,	3.6	1
602	Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis.. <i>Cancer Treatment Reviews</i> , 2022 , 104, 102354	14.4	0
601	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. 2022 , 10,		2
600	Evolution of low HER2 expression between early and advanced-stage breast cancer.. <i>European Journal of Cancer</i> , 2022 , 163, 35-43	7.5	5
599	Global challenges and policy solutions in breast cancer control.. <i>Cancer Treatment Reviews</i> , 2022 , 104, 102339	14.4	2
598	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. <i>Breast Cancer Research and Treatment</i> , 2022 , 1	4.4	0
597	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	5
596	ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.. <i>Annals of Oncology</i> , 2022 ,	10.3	2
595	Immunotherapy for early triple negative breast cancer: research agenda for the next decade.. <i>Npj Breast Cancer</i> , 2022 , 8, 23	7.8	7
594	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022 , 82, PD8-01-PD8-01	10.1	1
593	Abstract GS3-03: Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities. <i>Cancer Research</i> , 2022 , 82, GS3-03-GS3-03	10.1	
592	Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. <i>Cancer Research</i> , 2022 , 82, P4-06-08-P4-06-08	10.1	
591	Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. <i>Cancer Research</i> , 2022 , 82, OT1-02-02-OT1-02-02	10.1	
590	Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-13-04-P2-13-04	10.1	1
589	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 499	3.5	1
588	Bystander effect of antibody-drug conjugates: fact or fiction?. <i>Current Oncology Reports</i> , 2022 , 1	6.3	2
587	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 1143-1154	59.2	25

586	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.. <i>Frontiers in Molecular Biosciences</i> , 2022 , 9, 834651	5.6	7
585	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress.. <i>Expert Opinion on Investigational Drugs</i> , 2022 ,	5.9	3
584	Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?. <i>Lancet Oncology, The</i> , 2022 , 23, 325-328	21.7	0
583	How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?. <i>ESMO Open</i> , 2022 , 7, 100428	6	0
582	SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis.. <i>European Journal of Cancer</i> , 2022 , 166, 202-207	7.5	0
581	Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102395	14.4	2
580	Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.. <i>Annals of Oncology</i> , 2022 ,	10.3	
579	Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. <i>Breast</i> , 2022 , 64, 100-111	3.6	1
578	Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2867-2878	3.8	3
577	Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.. <i>Annals of Oncology</i> , 2021 ,	10.3	11
576	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021 , 32, 1475-1495	10.3	59
575	Distribution of the workforce involved in cancer care: a systematic review of the literature. <i>ESMO Open</i> , 2021 , 6, 100292	6	1
574	370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial 2021 , 9, A398-A398		
573	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2021 ,	220.7	10
572	Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 2021 , 9,		4
571	Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. <i>Cancers</i> , 2021 , 13,	6.6	4
570	Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2021 ,	7.5	5
569	Novel immune targets for the treatment of triple-negative breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 1-20	6.4	1

568	Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. <i>ESMO Open</i> , 2021 , 6, 100309	6	3
567	Targeting brain metastases in breast cancer.. <i>Cancer Treatment Reviews</i> , 2021 , 103, 102324	14.4	6
566	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. <i>JAMA Oncology</i> , 2021 ,	13.4	9
565	National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. <i>Lancet Oncology, The</i> , 2021 , 22, 1632-1642	21.7	13
564	Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 ,	12.9	3
563	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. <i>Cancers</i> , 2021 , 13,	6.6	1
562	Seroconversion rate after vaccination against COVID-19 in cancer patients-a systematic review. <i>Annals of Oncology</i> , 2021 ,	10.3	12
561	Precision Cancer Medicine: Large Studies Indicate Steady Progress. <i>Cancer Discovery</i> , 2021 , 11, 2677-2678	14.4	1
560	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. <i>Breast Cancer Research</i> , 2021 , 23, 38	8.3	4
559	PIK3CA Mutation Assessment in HR+/HER2- Metastatic Breast Cancer: Overview for Oncology Clinical Practice. <i>Journal of Molecular Pathology</i> , 2021 , 2, 42-54	0.4	3
558	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021 , 94, 102169	14.4	4
557	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021 , 145, 197-209	7.5	3
556	Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 159, 103223	7	19
555	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021 , 27, 3443-3455 ²	12.9	18
554	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 313-319	19.4	59
553	Commentary: SARS-CoV-2 vaccines and cancer patients. <i>Annals of Oncology</i> , 2021 , 32, 569-571	10.3	28
552	Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 3620-3629 ¹⁸	12.9	18
551	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 2021 , 9,		5

550	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 573-584	13.4	65
549	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. <i>Lung Cancer</i> , 2021 , 154, 151-160	5.9	12
548	SARS-CoV-2 vaccines for cancer patients: a call to action. <i>European Journal of Cancer</i> , 2021 , 148, 316-327	7.5	26
547	Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 323-337	4.4	6
546	Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2564-2564	2.2	6
545	A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2624-2624	2.2	2
544	Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial. <i>European Journal of Cancer</i> , 2021 , 148, 382-394	7.5	5
543	Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. <i>Lung Cancer</i> , 2021 , 155, 127-135	5.9	2
542	Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1043-1043	2.2	3
541	Breast cancer. <i>Lancet, The</i> , 2021 , 397, 1750-1769	40	126
540	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. <i>European Journal of Cancer</i> , 2021 , 148, 134-145	7.5	3
539	Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients. <i>European Journal of Cancer</i> , 2021 , 148, 277-286	7.5	1
538	Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9089-9089	2.2	3
537	SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS2657-TPS2657	2.2	0
536	KY1044 to target the ICOS pathways inducing intratumoral Treg depletion and agonism of effector T cells: Preliminary pharmacodynamic markers from a phase 1/2 multicenter trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2626-2626	2.2	
535	Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3079-3079	2.2	2
534	Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stage I/II aggressive breast cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3036-3036	2.2	1
533	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 , 149, 134-152	7.5	13

532	Antibody-Drug Conjugates for the Treatment of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	8
531	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 162, 103354	7	6
530	COVID-19 vaccines in patients with cancer. <i>Lancet Oncology, The</i> , 2021 , 22, 738-739	21.7	5
529	Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. <i>ESMO Open</i> , 2021 , 6, 100106	6	5
528	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , 2021 , 6, 100117	6	11
527	The global landscape of drug development of trastuzumab biosimilars.. <i>Journal of Cancer Policy</i> , 2021 , 28, 100273	1	1
526	Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. <i>Cancer Treatment Reviews</i> , 2021 , 97, 102205	14.4	7
525	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 150, 155-167	7.5	15
524	The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey.. <i>Journal of Cancer Policy</i> , 2021 , 28, 100285	1	5
523	Mastering the Use of Novel Anti-HER2 Treatment Options. <i>JCO Oncology Practice</i> , 2021 , 17, 605-606	2.3	1
522	Association of Breast Cancer Irradiation With Cardiac Toxic Effects: A Narrative Review. <i>JAMA Oncology</i> , 2021 , 7, 924-932	13.4	1
521	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021 , 11, 2796-2811	24.4	10
520	Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. <i>International Journal of Cancer</i> , 2021 , 149, 1455-1462	7.5	4
519	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 959-969	21.7	48
518	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 438-446	12.9	6
517	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1875, 188487	11.2	9
516	Margetuximab for the treatment of HER2-positive metastatic breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 127-133	5.4	12
515	CDK4/6 inhibitors for HRHER2 early stage breast cancer - when to escalate treatment?. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 67-68	19.4	1

514	ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. <i>Annals of Oncology</i> , 2021 , 32, 337-350	10.3	24
513	Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2021 , 92, 102133	14.4	2
512	Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. <i>Annals of Oncology</i> , 2021 , 32, 113-119	10.3	30
511	New anti-HER2 agents for brain metastasis: histology-agnostic weapons?. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 879-881	4.4	2
510	Development of a cure model for the estimation of long-term outcomes in patients with microsatellite instability(MSI)-high metastatic colorectal cancer (mCRC) receiving immune-checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 87-87	2.2	
509	Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 41-49	2.2	5
508	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology, The</i> , 2021 , 22, e18-e28	21.7	13
507	Clinical development and current role of margetuximab for the treatment of breast cancer. <i>Drugs of Today</i> , 2021 , 57, 551-558	2.5	2
506	Safety and efficacy of antiPD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9-9	2.2	22
505	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1143-1155	9.7	8
504	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 467-467	2.2	7
503	Antibody-drug conjugates in solid tumors: a look into novel targets. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 20	22.4	36
502	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021 , 13,	6.6	4
501	Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression. <i>Breast Cancer Research and Treatment</i> , 2021 , 186, 885-886	4.4	1
500	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021 , 7, 162-172	3.7	16
499	Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021 , 98, 102223	14.4	8
498	Alpelisib in combination with everolimus and exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. <i>European Journal of Cancer</i> , 2021 , 151, 49-62	7.5	5
497	Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. <i>European Journal of Cancer</i> , 2021 , 153, 162-167	7.5	2

496	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. <i>Annals of Oncology</i> , 2021 , 32, 1496-1510	10.3	7
495	Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. <i>Current Oncology</i> , 2021 , 28, 3384-3392	2.8	1
494	Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3541-3545	2.2	2
493	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 2021 , 9,		2
492	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 491-501	18.1	41
491	Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB Trial). <i>European Journal of Cancer</i> , 2021 , 153, 223-233	7.5	2
490	Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	7
489	A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 5760-5770	12.9	6
488	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102253	14.4	8
487	1583P COVID-19 related risk in patients enrolled in early-phase clinical trials. <i>Annals of Oncology</i> , 2021 , 32, S1140-S1141	10.3	78
486	Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-15	5.9	3
485	The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. <i>European Journal of Cancer</i> , 2021 , 154, 175-189	7.5	5
484	Should temozolomide be used on the basis of O-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102261	14.4	2
483	A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1559-1569	8.9	10
482	LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. <i>Annals of Oncology</i> , 2021 , 32, S1287-S1288	10.3	26
481	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
480	Therapeutic cancer vaccines revamping: technology advancements and pitfalls. <i>Annals of Oncology</i> , 2021 , 32, 1537-1551	10.3	12
479	Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1233-1252	3.8	3

478	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44
477	Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. <i>Cancer Treatment Reviews</i> , 2021 , 100, 102281	14.4	1
476	Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. <i>European Journal of Cancer</i> , 2021 , 157, 40-49	7.5	2
475	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.. <i>European Heart Journal</i> , 2021 ,	9.5	21
474	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer.. <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-13	3.5	2
473	Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer.. <i>Cancers</i> , 2021 , 14,	6.6	1
472	LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology. <i>Annals of Oncology</i> , 2020 , 31, S1205-S1206	10.3	3
471	LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study. <i>Annals of Oncology</i> , 2020 , 31, S1206	10.3	4
470	442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). <i>Annals of Oncology</i> , 2020 , 31, S1413-S1414	10.3	2
469	Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> , 2020 , 6, 1357-1362	3.7	5
468	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , 2020 , 5, 182-223	1.3	6
467	Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. <i>ESC Heart Failure</i> , 2020 , 7, 1452-1466	3.7	8
466	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020 , 25, 803-809	5.7	17
465	Risk of coronavirus disease 2019 in patients treated for cancer: An immune response-based hypothesis. <i>European Journal of Cancer</i> , 2020 , 134, 6-8	7.5	1
464	In Reply. <i>Oncologist</i> , 2020 , 25, e1252-e1253	5.7	
463	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response 2020 , 8,		23
462	Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. <i>Nature Communications</i> , 2020 , 11, 2332	17.4	42
461	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 17	7.8	54

460	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2610-2619	2.2	134
459	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , 2020 , 25, e1426-e1427	5.7	5
458	Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. <i>British Journal of Cancer</i> , 2020 , 123, 694-697	8.7	29
457	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. <i>European Journal of Cancer</i> , 2020 , 135, 62-65	7.5	26
456	Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 381-387	2.7	1
455	Pharmacological management of male breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1493-1504		
454	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020 , 25, e936-e945	5.7	356
453	Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 347-354	4.4	22
452	The global landscape of drug development for kidney cancer. <i>Cancer Treatment Reviews</i> , 2020 , 89, 102061	1.4	1
451	Theoretical and practical knowledge curriculum for European Breast Surgeons. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 717-736	3.6	4
450	Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020 , 5, 7-22	1.6	1
449	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 105-124	220.7	63
448	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1070-1080	2.2	9
447	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020 , 31, 171-190	10.3	262
446	Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101963	14.4	28
445	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 2131-2139	12.9	22
444	The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. <i>European Journal of Cancer</i> , 2020 , 132, 199-206	7.5	43
443	Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 221-224	4.4	3

442	ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020 , 31, 674-696	10.3	80
441	Biologic therapy for advanced breast cancer: recent advances and future directions. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1009-1024	5.4	11
440	Master protocols in immuno-oncology: do novel drugs deserve novel designs? 2020 , 8,		6
439	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1951-1962	2.2	74
438	Effect of the COVID-19 pandemic on cancer treatment and research. <i>Lancet Haematology</i> , 2020 , 7, e432-e435	14.6	71
437	Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. <i>Breast</i> , 2020 , 52, 8-16	3.6	113
436	Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies. <i>Blood</i> , 2020 , 136, 13-14	2.2	
435	Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis 2020 ,		19
434	A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1039-1039	2.2	13
433	SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1040-1040	2.2	2
432	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 109-109	2.2	37
431	Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9515-9515	2.2	43
430	First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 128-128	2.2	2
429	Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 218-218	2.2	3
428	Combinations using checkpoint blockade to overcome resistance. <i>Ecancermedicalscience</i> , 2020 , 14, 11482.7		6
427	Tailoring Chemotherapy and Biological Treatment in Young Patients with EBC 2020 , 99-111		
426	1678P_PR The impact of COVID-19 pandemic on cancer care: A global collaborative study. <i>Annals of Oncology</i> , 2020 , 31, S1209-S1210	10.3	4
425	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 100-107	13.4	34

424	Expression of tumor-associated antigens in breast cancer subtypes. <i>Breast</i> , 2020 , 49, 202-209	3.6	5
423	CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. <i>Lancet Oncology, The</i> , 2020 , 21, 191-192	21.7	5
422	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 597-609	59.2	396
421	Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. <i>European Journal of Cancer</i> , 2020 , 139, 92-98	7.5	7
420	Repurposing anticancer drugs for the management of COVID-19. <i>European Journal of Cancer</i> , 2020 , 141, 40-61	7.5	30
419	Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. <i>JCO Global Oncology</i> , 2020 , 6, 1428-1438	3.7	92
418	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020 , 6, 1461-1471	3.7	26
417	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020 , 6, 54	7.8	58
416	How to treat lobular cancer in the adjuvant setting?. <i>Current Opinion in Oncology</i> , 2020 , 32, 561-567	4.2	2
415	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020 , 31, 1623-1649	10.3	282
414	19130 Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). <i>Annals of Oncology</i> , 2020 , 31, S1084	10.3	18
413	LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET). <i>Annals of Oncology</i> , 2020 , 31, S62	10.3	7
412	Progresses Toward Precision Medicine in -altered Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 6102-6111	6.1	13
411	Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity. <i>European Journal of Cancer</i> , 2020 , 141, 218-224	7.5	6
410	Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. <i>Journal of Translational Medicine</i> , 2020 , 18, 446	8.5	1
409	Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer. <i>Lancet Oncology, The</i> , 2020 , 21, 1543-1545	21.7	1
408	Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020 , 383, 693-694	59.2	4
407	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. <i>Cancer Treatment Reviews</i> , 2020 , 89, 102085	14.4	22

406	Cancer Patients and Risk of Mortality for COVID-19. <i>Cancer Cell</i> , 2020 , 38, 161-163	24.3	26
405	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , 2020 , 31, 1320-1335	10.3	121
404	Antibody-drug conjugates in breast cancer: the chemotherapy of the future?. <i>Current Opinion in Oncology</i> , 2020 , 32, 494-502	4.2	8
403	A role for the immune system in advanced laryngeal cancer. <i>Scientific Reports</i> , 2020 , 10, 18327	4.9	6
402	Adjuvant treatment of early male breast cancer. <i>Current Opinion in Oncology</i> , 2020 , 32, 594-602	4.2	2
401	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020 , 5,	6	74
400	2750 Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM). <i>Annals of Oncology</i> , 2020 , 31, S349-S350	10.3	3
399	Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102089	14.4	15
398	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , 2020 , 139, 43-50	7.5	147
397	Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. <i>Oncologist</i> , 2020 , 25, e1732-e1742	5.7	6
396	Management of Cardiac Toxicity Induced by Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
395	Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 480-504	220.7	16
394	Dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1234-1243	21.7	120
393	Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. <i>ESMO Open</i> , 2020 , 5, e001081	6	1
392	Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic. <i>European Journal of Cancer</i> , 2020 , 132, 8-10	7.5	9
391	Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020 , 26, 354-363	12.9	19
390	How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience. <i>Oncologist</i> , 2020 , 25, 463-467	5.7	24
389	Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-11	7.1	4

388	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-13	3.6	4
387	European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. <i>Breast Care</i> , 2019 , 14, 359-365	2.4	4
386	What therapies are on the horizon for HER2 positive breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 811-822	3.5	2
385	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. <i>European Journal of Cancer</i> , 2019 , 120, 1-9	7.5	27
384	Are all cyclin-dependent kinases 4/6 inhibitors created equal?. <i>Npj Breast Cancer</i> , 2019 , 5, 27	7.8	44
383	Evaluating triptorelin as a treatment option for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1809-1818	4	1
382	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019 , 79, 1609-1624	12.1	3
381	EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. <i>Breast</i> , 2019 , 44, 90-93	3.6	16
380	Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. <i>Cancer Treatment Reviews</i> , 2019 , 74, 21-28	14.4	16
379	Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. <i>Cells</i> , 2019 , 8,	7.9	7
378	Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?. <i>European Journal of Cancer</i> , 2019 , 117, 1-4	7.5	2
377	The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review. <i>European Journal of Cancer</i> , 2019 , 117, 14-31	7.5	48
376	Systemic Impact of Breast Reconstruction 2019 , 769-774		
375	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TRENd trial. <i>Breast Cancer Research</i> , 2019 , 21, 71	8.3	14
374	An analysis of available biomarker data for targeting cyclin-dependent kinases 4 and 6 (CDK4/6) in breast cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019 , 4, 129-138	1.6	1
373	Recent advances in triple negative breast cancer: the immunotherapy era. <i>BMC Medicine</i> , 2019 , 17, 90	11.4	161
372	Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3 β -MCL-1 Axis. <i>Cancer Cell</i> , 2019 , 35, 798-815.e5	24.3	108
371	Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review. <i>JAMA Oncology</i> , 2019 , 5, 1347-1354	13.4	34

370	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019 , 30, 766-773	10.3	46
369	Peptide vaccines in early breast cancer. <i>Breast</i> , 2019 , 44, 128-134	3.6	7
368	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology</i> , 2019 , 20, 371-382	21.7	200
367	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019 , 30, 1541-1557	10.3	288
366	Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2019 , 118, 41-48	7.5	18
365	Biosimilars for breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1015-1021	5.4	2
364	Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy. <i>Annals of Oncology</i> , 2019 , 30, v55	10.3	3
363	Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer. <i>Annals of Oncology</i> , 2019 , 30, v790	10.3	2
362	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. <i>European Journal of Cancer</i> , 2019 , 122, 22-41	7.5	1
361	Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors 2019 ,		9
360	Abstract CT183: Phase (Ph) I/II study of MBG453 spartalizumab (PDR001) in patients (pts) with advanced malignancies 2019 ,		21
359	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1000-1000	2.2	56
358	FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4511-4511	2.2	27
357	Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 580-580	2.2	2
356	Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6018-6018	2.2	29
355	Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8516-8516	2.2	9
354	Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9008-9008	2.2	62
353	Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 187-187	2.2	53

352	BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 358-358	2.2	22
351	Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. 2019 , 2, 43-52		0
350	Toward precision medicine in inflammatory breast cancer.. <i>Translational Cancer Research</i> , 2019 , 8, S469-S478		
349	Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1168, 9-30	3.6	45
348	Homologous recombination deficiency in triple negative breast cancer. <i>Breast</i> , 2019 , 45, 15-21	3.6	31
347	WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. <i>Breast Cancer Research</i> , 2019 , 21, 123	8.3	14
346	Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. <i>Breast Care</i> , 2019 , 14, 373-381	2.4	4
345	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2019 , 24, e1034-e1043	5.7	4
344	TRIPLE NEGATIVE ADVANCED BREAST CANCER: BIOLOGY AND RESISTANCE. <i>Breast</i> , 2019 , 48, S25	3.6	
343	Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. <i>Current Opinion in Oncology</i> , 2019 , 31, 472-479	4.2	2
342	Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. <i>Annals of Oncology</i> , 2019 , 30, 1941-1949	10.3	78
341	Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). <i>Annals of Oncology</i> , 2019 , 30, ix122	10.3	7
340	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2019 , 30, 236-242	10.3	70
339	A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 9-16	3.8	2
338	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019 , 30, 397-404	10.3	313
337	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 133, 171-182	7	45
336	Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. <i>Drug Safety</i> , 2019 , 42, 247-262	5.1	44
335	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019 , 38, 835-844	4	17

334	The role of histone deacetylase inhibitors in metastatic breast cancer. <i>Breast</i> , 2019 , 43, 130-134	3.6	22
333	Targeting DNA Repair. <i>Handbook of Experimental Pharmacology</i> , 2018 , 249, 161-180	3.2	
332	Targeting the microenvironment in solid tumors. <i>Cancer Treatment Reviews</i> , 2018 , 65, 22-32	14.4	189
331	Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?. <i>Lancet Oncology, The</i> , 2018 , 19, 434-436	21.7	2
330	A new approach to assess drug sensitivity in cells for novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018 , 13, 339-346	6.2	6
329	Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. <i>Lancet Oncology, The</i> , 2018 , 19, 323-336	21.7	59
328	Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 299-305	4	3
327	Adjuvant Chemotherapy 2018 , 439-445		
326	The use of breast imaging for predicting response to the adjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. <i>European Journal of Cancer</i> , 2018 , 89, 42-48	7.5	9
325	Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. <i>Annals of Oncology</i> , 2018 , 29, 281-282	10.3	2
324	Cetuximab for treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 483-493	3.4	22
323	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one Trial. <i>European Journal of Cancer</i> , 2018 , 94, 126-137	7.5	98
322	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 162-169	10.3	26
321	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. <i>Breast Cancer: Targets and Therapy</i> , 2018 , 10, 23-29	3.9	9
320	Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?. <i>Breast</i> , 2018 , 41, 133-135	3.6	5
319	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) <i>Annals of Oncology</i> , 2018 , 29, 1634-1657	10.3	645
318	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TRENd trial. <i>Annals of Oncology</i> , 2018 , 29, 1748-1754	10.3	61
317	Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study 2018 ,		27

316	A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3094-3094	2.2	5
315	First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3540-3540	2.2	23
314	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4032-4032	2.2	3
313	BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4512-4512	2.2	14
312	Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 58-58	2.2	2
311	A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. <i>Oncotarget</i> , 2018 , 9, 31709-31718	3.3	18
310	Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 571-571	2.2	
309	Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients. <i>European Journal of Cancer</i> , 2018 , 89, 49-55	7.5	12
308	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. <i>ESMO Open</i> , 2018 , 3, e000422	6	30
307	Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation. <i>Annals of Oncology</i> , 2018 , 29, viii525	10.3	3
306	Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-16	3.6	1
305	Cancer Evolution as the New Frontier of Precision Medicine. <i>Handbook of Experimental Pharmacology</i> , 2018 , 249, 289-297	3.2	1
304	Report on the status of women occupying leadership roles in oncology. <i>ESMO Open</i> , 2018 , 3, e000423	6	17
303	Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review. <i>Annals of Oncology</i> , 2018 , 29, viii104	10.3	2
302	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 132, 125-129	7	14
301	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1385-1393	21.7	195
300	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , 2018 , 42, 41-49	3.6	49
299	Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. <i>European Journal of Cancer</i> , 2018 , 97, 1-6	7.5	18

298	Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. <i>Seminars in Cancer Biology</i> , 2018 , 52, 253-258	12.7	5
297	Talking to patients about biosimilars. <i>Future Oncology</i> , 2018 , 14, 2403-2414	3.6	8
296	Inflammatory breast cancer and chest wall disease: The oncologist perspective. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1142-1147	3.6	4
295	Edoxaban for Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018 , 379, 95-96	59.2	10
294	The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. <i>Current Oncology Reports</i> , 2017 , 19, 1	6.3	38
293	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2017 , 75, 245-258	7.5	66
292	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncotmunology</i> , 2017 , 6, e1253654	7.2	87
291	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. <i>Breast Cancer Research and Treatment</i> , 2017 , 162, 479-488	4.4	10
290	Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 575-581	5.5	16
289	Breast Cancer Cardio-Oncology 2017 , 241-252		
288	Treatment of Hypertension in Patients Receiving Cancer Therapy 2017 , 105-123		1
287	3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017 , 28, 16-33	10.3	241
286	Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. <i>Breast</i> , 2017 , 34, 89-95	3.6	13
285	SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. <i>Medical Oncology</i> , 2017 , 34, 75	3.7	17
284	3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <i>Breast</i> , 2017 , 31, 244-259	3.6	137
283	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2017 , 28, 321-328	10.3	55
282	Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases. <i>European Journal of Radiology</i> , 2017 , 95, 96-101	4.7	5
281	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017 , 1868, 527-537	11.2	29

280	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <i>European Journal of Cancer</i> , 2017 , 86, 257-265	7.5	21
279	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017 , 28, 1700-1712	10.3	586
278	Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 2320-2328	3.3	51
277	Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2600-2603	2.2	6
276	Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. <i>Current Opinion in Oncology</i> , 2017 , 29, 428-433	4.2	2
275	Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures. <i>Current Opinion in Oncology</i> , 2017 , 29, 411-427	4.2	24
274	Entinostat for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 965-971	5.9	33
273	Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017 , 12, 152-158	2.4	9
272	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Metastatic Tumors. <i>Advances in Anatomic Pathology</i> , 2017 , 25, 211-235	5.1	299
271	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017 , 25, 211-235	5.1	293
270	Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2017 , 87, 164-171	7.5	7
269	Targeting Immune Checkpoint 2017 , 781-785		1
268	Targeting PI3K/AKT/mTOR Pathway 2017 , 787-793		
267	Targeting Genome Instability and DNA Repair 2017 , 795-805		
266	Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. <i>Breast</i> , 2017 , 31, 51-56	3.6	78
265	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017 , 19, 9-42	12.3	189
264	Over-using chemotherapy in the adjuvant setting. <i>Breast</i> , 2017 , 31, 303-308	3.6	8
263	From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. <i>Breast</i> , 2017 , 31, 241-243	3.6	1

262	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2017 , 28, v68	10.3	3
261	MA 12.02 Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1847-S1848	8.9	3
260	Efficacy and Safety of Platinum and Metronomic Cyclophosphamide in Triple Negative Breast Cancer. <i>Breast</i> , 2017 , 36, S47	3.6	2
259	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. <i>BioMed Research International</i> , 2017 , 2017, 4719194	3	53
258	Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) 2017 ,		3
257	Abstract OT1-02-07: SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer 2017 ,		2
256	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1002-1002	2.2	8
255	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1008-1008	2.2	82
254	Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9520-9520	2.2	136
253	A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1107-TPS1107	2.2	1
252	Chest Wall Disease: The Clinical Continuum Between Inflammatory and Lymphangitic Breast Cancer 2017 , 719-727		
251	Targeting FGFR Pathway in Breast Cancer 2017 , 819-822		
250	Integrating Next-Generation Sequencing Data in Trial Design 2017 , 823-827		
249	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 575-575	2.2	1
248	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2016 , 37, 2768-2801	9.5	1249
247	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 360-74	5.4	33
246	Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. <i>Breast</i> , 2016 , 28, 191-8	3.6	82
245	Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?. <i>European Journal of Surgical Oncology</i> , 2016 , 42, 1780-1786	3.6	17

244	Understanding cognitive processes behind acceptance or refusal of phase I trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 69-73	7	16
243	Biosimilars: Extrapolation for oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 104, 131-7	7	35
242	Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. <i>Pharmacology & Therapeutics</i> , 2016 , 157, 120-4	13.9	66
241	A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 319-30	4.4	21
240	A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 301-10	4.4	27
239	Response to Letters Regarding Article, "Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy". <i>Circulation</i> , 2016 , 133, e363	16.7	3
238	The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine. <i>Annals of Oncology</i> , 2016 , 27, 6-8	10.3	3
237	Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer 2016 ,		7
236	Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified oestrogen rEceptor poSitive metaStatic breast canCEr 2016 ,		2
235	Abstract OT3-01-05: PANACEA (IBCSG 45-13/BIG 4-13): A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant, HER2-positive, metastatic breast cancer 2016 ,		5
234	Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2500-2500	2.2	11
233	Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2566-2566	2.2	6
232	SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS630-TPS630	2.2	3
231	RNAi screens identify CHD4 as an essential gene in breast cancer growth. <i>Oncotarget</i> , 2016 , 7, 80901-80915	3.5	24
230	Impact of autoimmune diseases on outcome of patients with early breast cancer. <i>Oncotarget</i> , 2016 , 7, 51184-51192	3.3	8
229	Future perspectives in cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2016 , 4, 273	3.2	24
228	Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies: The CORNUCOPIA study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS11615-TPS11615	2.2	22
227	Arrhythmias and QTc Prolongations 2016 , 245-269		

226	Highlights from the 38th SABCS annual meeting, 8th - 12th December 2015, San Antonio, USA. <i>Ecancermedicalscience</i> , 2016 , 10, 618	2.7	3
225	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 323-31	4.4	73
224	Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. <i>Journal of Cardiac Failure</i> , 2016 , 22, 465-71	3.3	40
223	Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. <i>Cancer Treatment Reviews</i> , 2016 , 50, 205-207	14.4	41
222	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 309-25	220.7	287
221	HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. <i>Anticancer Research</i> , 2016 , 36, 3537-40	2.3	1
220	QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. <i>Targeted Oncology</i> , 2015 , 10, 27-43	5	19
219	Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 1288-92	3.6	23
218	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. <i>Modern Pathology</i> , 2015 , 28, 1185-201	9.8	144
217	Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. <i>Ecancermedicalscience</i> , 2015 , 9, 518	2.7	44
216	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015 , 26, 1280-91	10.3	127
215	Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. <i>Breast</i> , 2015 , 24, 263-71	3.6	11
214	Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 2538-47	3.4	18
213	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015 , 26, 1533-46	10.3	1122
212	Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. <i>Circulation</i> , 2015 , 131, 1981-8	16.7	776
211	New approaches for improving outcomes in breast cancer in Europe. <i>Breast</i> , 2015 , 24, 321-30	3.6	37
210	Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 51-5	4.8	6
209	Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. <i>Cancer Treatment Reviews</i> , 2015 , 41, 793-7	14.4	22

208	Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. <i>Clinical Breast Cancer</i> , 2015 , 15, e237-41	3	8
207	Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment 2015 , 341-361		
206	Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. <i>Current Opinion in Oncology</i> , 2015 , 27, 445-51	4.2	32
205	Targeting fibroblast growth factor receptor pathway in breast cancer. <i>Current Opinion in Oncology</i> , 2015 , 27, 452-6	4.2	10
204	Lessons from the first e cancer symposium on angiogenesis in gastric cancer. <i>Ecancermedicalscience</i> , 2015 , 9, 553	2.7	
203	Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. <i>BioMed Research International</i> , 2015 , 2015, 183523	3	13
202	Immunotherapy of Breast Cancer. <i>Progress in Tumor Research</i> , 2015 , 42, 30-43		25
201	Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. <i>Cancer Treatment Reviews</i> , 2015 , 41, 61-8	14.4	42
200	Clinical considerations for the development of biosimilars in oncology. <i>MAbs</i> , 2015 , 7, 286-93	6.6	39
199	Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. <i>Annals of Oncology</i> , 2015 , 26, 682-687	10.3	40
198	Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1068-1068	2.2	2
197	Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2590-2590	2.2	2
196	Expert perspectives on biosimilar monoclonal antibodies in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 233-9	4.4	41
195	Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. <i>Cancer Treatment Reviews</i> , 2014 , 40, 648-55	14.4	88
194	Dendritic cell-based vaccines: clinical applications in breast cancer. <i>Immunotherapy</i> , 2014 , 6, 349-60	3.8	29
193	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014 , 23, 69-75	3.6	72
192	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. <i>European Journal of Cancer</i> , 2014 , 50, 277-89	7.5	163
191	Dinaciclib for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1305-12	5.9	31

190	Immune approaches to the treatment of breast cancer, around the corner?. <i>Breast Cancer Research</i> , 2014 , 16, 204	8.3	33
189	Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. <i>Breast Cancer Research</i> , 2014 , 16, 205	8.3	43
188	No link between breast cancer and meningioma: results from a large monoinstitutional retrospective analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 215-7	4	9
187	Reply to L.K. Mell et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1090-1	2.2	
186	Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 599-610	5.9	13
185	Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. <i>Annals of Oncology</i> , 2014 , 25, 611-618	10.3	267
184	Optimal adjuvant chemotherapy in breast cancer: selection of agents. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 605-11	3.8	3
183	Successes and limitations of targeted cancer therapy in breast cancer. <i>Progress in Tumor Research</i> , 2014 , 41, 15-35		23
182	Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. <i>Pharmaceuticals</i> , 2014 , 7, 943-53	5.2	55
181	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. <i>Breast Cancer Research</i> , 2014 , 16, R65	8.3	109
180	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014 , 25, 1979-1987	10.3	101
179	Tumor-stroma crosstalk: targeting stroma in breast cancer. <i>Current Opinion in Oncology</i> , 2014 , 26, 551-5	4.2	37
178	Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". <i>Toxins</i> , 2014 , 6, 914-33	4.9	51
177	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1134-TPS1134	2.2	1
176	From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26-30th September 2014. <i>Ecancermedicalscience</i> , 2014 , 8, 472	2.7	2
175	Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. <i>Ecancermedicalscience</i> , 2014 , 8, 463	2.7	25
174	Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 610-610	2.2	
173	Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?. <i>Anticancer Research</i> , 2014 , 34, 6677-83	2.3	11

172	Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. <i>European Journal of Surgical Oncology</i> , 2013 , 39, 260-5	3.6	25
171	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013 , 24, 2206-23	10.3	2048
170	Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. <i>Breast</i> , 2013 , 22, 650-6	3.6	55
169	High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy. <i>European Journal of Cancer</i> , 2013 , 49, 3083-92	7.5	11
168	Molecular pathways: human leukocyte antigen G (HLA-G). <i>Clinical Cancer Research</i> , 2013 , 19, 5564-71	12.9	86
167	Tailoring adjuvant treatments for the individual patient with luminal breast cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 703-14, vii-viii	3.1	5
166	Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. <i>European Journal of Cancer</i> , 2013 , 49, 3588-97	7.5	41
165	Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in Pt(II) complexes on human carcinoma cell lines: a comparative study with cisplatin. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 2379-2386	3.4	20
164	Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 28-33	12.9	147
163	Best management of locally advanced inoperable breast cancer. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 289-90	1.6	2
162	Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. <i>Lancet Oncology</i> , 2013 , 14, 962-70	21.7	143
161	Locoregional recurrence in patients with HER2 positive breast cancer. <i>Breast</i> , 2013 , 22, 856-62	3.6	11
160	Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. <i>Breast</i> , 2013 , 22 Suppl 2, S96-9	3.6	5
159	Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2013 , 39, 44-50	14.4	57
158	Evaluation of fat grafting safety in patients with intraepithelial neoplasia: a matched-cohort study. <i>Annals of Oncology</i> , 2013 , 24, 1479-84	10.3	143
157	Immunotherapeutics for breast cancer. <i>Current Opinion in Oncology</i> , 2013 , 25, 602-8	4.2	23
156	HER2 signaling pathway and trastuzumab cardiotoxicity. <i>Future Oncology</i> , 2013 , 9, 179-81	3.6	12
155	Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. <i>Acta Oncologica</i> , 2013 , 52, 1649-56	3.2	43

154	End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3711-8	2.2	205
153	Abstract OT2-6-01: Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse endocrine resistance - TReEnd trial) 2013 ,		3
152	Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study 2013 ,		3
151	Tumour dormancy and clinical implications in breast cancer. <i>Ecancermedicalscience</i> , 2013 , 7, 320	2.7	20
150	A review of the CTRC-AACR San Antonio Breast Cancer Symposium 2012. <i>Ecancermedicalscience</i> , 2013 , 7, 291	2.7	
149	Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?. <i>Ecancermedicalscience</i> , 2013 , 7, 299	2.7	14
148	Systemic Impact of Breast Reconstruction 2013 , 417-421		
147	Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 617-617	2.2	
146	ALGA: A cancer patient profiling tool to improve physician-patient communicationAn analysis in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9582-9582	2.2	
145	Second primary tumors in cancer patients: A retrospective analysis based on institutional tumor registry.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1595-1595	2.2	
144	Biopsy of liver metastasis for women with breast cancer: impact on survival. <i>Breast</i> , 2012 , 21, 284-8	3.6	18
143	Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 340-6	3	37
142	Risk of locoregional recurrence in patients with false-negative frozen section or close margins of retroareolar specimen in nipple-sparing mastectomy. <i>Annals of Surgical Oncology</i> , 2012 , 19, 4117-23	3.1	52
141	Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii155-66	10.3	505
140	Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. <i>Breast Journal</i> , 2012 , 18, 470-4	1.2	24
139	New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. <i>Cancer Treatment Reviews</i> , 2012 , 38, 303-10	14.4	24
138	Targeting the subtypes of breast cancer: rethinking investigational drugs. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 191-204	5.9	1
137	Ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in pancreatic metastasis from renal cell carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 1258-61	2.7	8

136	Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 277-82	4.4	54
135	Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. <i>Annals of Oncology</i> , 2012 , 23, 2884-2890	10.3	2
134	"The only thing I know is that I know nothing": 5-fluorouracil in human milk. <i>Annals of Oncology</i> , 2012 , 23, 543-4	10.3	7
133	Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?. <i>Annals of Oncology</i> , 2012 , 23, 547-555	10.3	39
132	CMF revisited in the 21st century. <i>Annals of Oncology</i> , 2012 , 23, 305-11	10.3	18
131	Locoregional recurrence risk after lipofilling in breast cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 582-588	10.3	171
130	Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. <i>Annals of Oncology</i> , 2012 , 23, 2053-2058	10.3	78
129	Immunotherapy in breast cancer - towards a new understanding of both tumor and host. <i>Breast Care</i> , 2012 , 7, 258-60	2.4	1
128	A meta-analysis of receptor status discordance between primary breast cancer and metastases.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 546-546	2.2	1
127	Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma. <i>European Journal of Surgical Oncology</i> , 2011 , 37, 558-62	3.6	15
126	Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Annals of Oncology</i> , 2011 , 22, 2227-33	10.3	89
125	Immunity and autoimmunity: revising the concepts of response to breast cancer. <i>Breast</i> , 2011 , 20 Suppl 3, S71-4	3.6	16
124	Autologous fat transplantation in patients with breast cancer: "silencing" or "fueling" cancer recurrence?. <i>Breast</i> , 2011 , 20, 351-7	3.6	116
123	The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 369-78	4.4	9
122	Intraobserver and interobserver variability in the calculation of apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (DW-MRI) of breast tumours. <i>Radiologia Medica</i> , 2011 , 116, 466-76	6.5	19
121	Immunity and autoimmunity in breast cancer. <i>Breast Cancer Research</i> , 2011 , 13,	8.3	78
120	The triple-negative subtype: new ideas for the poorest prognosis breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 108-10	4.8	44
119	Cancer-testis antigen expression in triple-negative breast cancer. <i>Annals of Oncology</i> , 2011 , 22, 98-103	10.3	71

118	Nipple-sparing mastectomy--is it worth the risk?. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 742-7	19.4	44
117	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 147-51	4.8	55
116	PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study]. 2011 ,		8
115	Reply to D. Crivellari et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e258-e259	2.2	2
114	The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2010 , 46, 2926-35	7.5	125
113	Developing an effective breast cancer vaccine. <i>Cancer Control</i> , 2010 , 17, 183-90	2.2	30
112	High-intensity focused ultrasound effect in breast cancer nodal metastasis. <i>CardioVascular and Interventional Radiology</i> , 2010 , 33, 447-9	2.7	8
111	Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 211-7	4.4	65
110	Cardiac toxicity from systemic cancer therapy: a comprehensive review. <i>Progress in Cardiovascular Diseases</i> , 2010 , 53, 94-104	8.5	125
109	Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 392-7	3	86
108	Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. <i>Breast</i> , 2010 , 19, 33-7	3.6	24
107	Abstract P6-12-02: A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer 2010 ,		3
106	Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Journal of Clinical Oncology</i> , 2010 , 28, CRA1008-CRA1008	2.2	13
105	Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5693-9	2.2	203
104	Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib. <i>Urologia Internationalis</i> , 2009 , 82, 196-202	1.9	3
103	Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. <i>Annals of Oncology</i> , 2009 , 20, 498-502	10.3	8
102	Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. <i>Journal of Chemotherapy</i> , 2009 , 21, 687-92	2.3	6
101	Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. <i>Oncology</i> , 2009 , 77, 358-65	3.6	8

100	Coagulation disorders in patients with cancer: nontunneled central venous catheter placement with US guidance--a single-institution retrospective analysis. <i>Radiology</i> , 2009 , 253, 249-52	20.5	21
99	QTc prolongation assessment in anticancer drug development: clinical and methodological issues. <i>Ecancermedicalscience</i> , 2009 , 3, 130	2.7	8
98	Systemic therapies for non-metastatic prostate cancer: review of the literature. <i>Onkologie</i> , 2009 , 32, 359-63		4
97	S15 The (last?) word about biomarkers for angiogenesis. <i>Breast</i> , 2009 , 18, S6-S7	3.6	2
96	Immunizing against breast cancer: a new swing for an old sword. <i>Breast</i> , 2009 , 18 Suppl 3, S51-4	3.6	14
95	Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 491-500	4.4	30
94	Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 138-9	8.9	4
93	Vinorelbine, cisplatin, and continuous infusion of 5-fluorouracil (ViFuP regimen) in carcinoma of unknown primary. <i>Journal of Clinical Oncology</i> , 2009 , 27, e20682-e20682	2.2	
92	Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma. <i>Ecancermedicalscience</i> , 2008 , 2, 102	2.7	
91	Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. <i>European Journal of Cancer</i> , 2008 , 44, 494-500	7.5	35
90	Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug. <i>Supportive Care in Cancer</i> , 2008 , 16, 313-314	3.9	
89	Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 65, 1-7	7	76
88	Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. <i>Prostate</i> , 2007 , 67, 603-4	4.2	16
87	Challenges and prospects of immunotherapy as cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007 , 1776, 108-23	11.2	27
86	Immunology and breast cancer: therapeutic cancer vaccines. <i>Breast</i> , 2007 , 16 Suppl 2, S20-6	3.6	19
85	S12 Immunity and breast cancer cells: Role of vaccination. <i>Breast</i> , 2007 , 16, S3-S4	3.6	
84	Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. <i>Supportive Care in Cancer</i> , 2007 , 15, 1213-7	3.9	12
83	Vaccine immunotherapy in breast cancer treatment: promising, but still early. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1225-41	3.5	33

82	Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1345-6; author reply 1346-7	9.7	4
81	To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 510-1		1
80	Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1210; author reply 1210-1	9.7	3
79	A dose finding pharmacokinetic study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3057-3057	2.2	5
78	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. <i>Anti-Cancer Drugs</i> , 2007 , 18, 949-54	2.4	8
77	Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. <i>Annals of Oncology</i> , 2006 , 17, 1174-5	10.3	12
76	"Burned out" phenomenon of the testis in retroperitoneal seminoma. <i>Acta Oncologica</i> , 2006 , 45, 335-6	3.2	13
75	Reply to Letter to the Editor: "Toxic epidermal necrolysis in patients with malignancies" by G. Gravante, G. Esposito, M. Marianetti, D. Delogu, G. Sconocchia & A. Montone (doi:10.1093/annonc/mdl089). <i>Annals of Oncology</i> , 2006 , 17, 1601-1602	10.3	0
74	Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. <i>Breast Cancer Research</i> , 2006 , 8, R4	8.3	53
73	Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. <i>Supportive Cancer Therapy</i> , 2006 , 3, 98-102		11
72	A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. <i>Lung Cancer</i> , 2006 , 54, 359-64	5.9	4
71	Breast cancer vaccines: a clinical reality or fairy tale?. <i>Annals of Oncology</i> , 2006 , 17, 750-62	10.3	61
70	A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2006 , 17, 1201-9	2.4	11
69	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , 2006 , 95, 289-97	8.7	37
68	What is the role of QTc prolongation assessment in new drugs development phase I oncology trials?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2006-2006	2.2	3
67	Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. <i>Anticancer Research</i> , 2006 , 26, 2375-80	2.3	0
66	Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. <i>Supportive Care in Cancer</i> , 2005 , 13, 194-5	3.9	6
65	Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. <i>Breast Cancer Research and Treatment</i> , 2005 , 93, 25-40	4.4	53

64	Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. <i>Annals of Oncology</i> , 2005 , 16, 1094-9	10.3	17
63	Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 461-2; author reply 462-3	9.7	3
62	Target-treatment and patients' selection: can we still neglect the timing of tissue collection?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6274-5; author reply 6275-6	2.2	2
61	Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7243-4; author reply 7244	2.2	3
60	Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 921-2; author reply 922	2.2	4
59	Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (<i>Ann Oncol</i> 2004; 15: 1543-1550): ... and in humans?. <i>Annals of Oncology</i> , 2005 , 16, 673	10.3	6
58	Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1867-74	2.2	148
57	Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2520-2520	2.2	6
56	Clinical results and impact on circulating endothelial cells (CEC) of treatment with combinations of interferon- β (IF), thalidomide (T) and celecoxib (C) in patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3193-3193	2.2	
55	Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. <i>Annals of Oncology</i> , 2004 , 15, 590-3	10.3	44
54	Drug-induced prolongation of the QT interval. <i>New England Journal of Medicine</i> , 2004 , 350, 2618-21; author reply 2618-21	59.2	14
53	Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. <i>Clinical Cancer Research</i> , 2004 , 10, 6622-8	12.9	293
52	CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. <i>Annals of Oncology</i> , 2004 , 15, 1850	10.3	1
51	Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4966-70	2.2	30
50	Male breast cancer: A special therapeutic problem. Anything new? (Review) 2004 , 24, 663		4
49	Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. <i>Cancer</i> , 2004 , 101, 1302-10	6.4	151
48	Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. <i>Clinical Breast Cancer</i> , 2004 , 5, 125-30	3	15
47	Systemic effects of surgery: Quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF- β) in patients with breast cancer who underwent limited or extended surgery. <i>Journal of Clinical Oncology</i> , 2004 , 22, 672-672	2.2	1

46	Systemic effects of surgery: Quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF- β) in patients with breast cancer who underwent limited or extended surgery. <i>Journal of Clinical Oncology</i> , 2004 , 22, 672-672	2.2	
45	Male breast cancer: a special therapeutic problem. Anything new? (Review). <i>International Journal of Oncology</i> , 2004 , 24, 663-70	1	22
44	Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study. <i>Bulletin Du Cancer</i> , 2004 , 91, E273-7	2.4	
43	Imatinib administration in two patients with liver metastases from GIST and severe jaundice. <i>British Journal of Cancer</i> , 2003 , 89, 1403-4	8.7	5
42	Catheter-related bloodstream infections, part II: specific pathogens and prevention. <i>Cancer Control</i> , 2003 , 10, 79-91	2.2	3
41	Preoperative chemotherapy is essential for conservative surgery of Askin tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003 , 125, 428-9	1.5	19
40	Venous thromboembolism and cancer: new issues for an old topic. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 48, 65-80	7	29
39	Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. <i>Pharmacological Reviews</i> , 2003 , 55, 57-103	22.5	58
38	Impact of limited pulmonary function on the management of resectable lung cancer. <i>Lung Cancer</i> , 2003 , 41, 71-9	5.9	23
37	Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. <i>Annals of Oncology</i> , 2003 , 14, 1477-83	10.3	9
36	Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. <i>Annals of Oncology</i> , 2003 , 14, 803-4	10.3	12
35	Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. <i>Anticancer Research</i> , 2003 , 23, 5023-30	2.3	5
34	Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2603-4; author reply 2605	2.2	1
33	Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. <i>Annals of Oncology</i> , 2002 , 13, 895-902	10.3	29
32	Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. <i>Annals of Oncology</i> , 2002 , 13, 161-6	10.3	15
31	Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients. <i>Oncology</i> , 2002 , 63, 370-7	3.6	6
30	Catheter-related bloodstream infections, part I: pathogenesis, diagnosis, and management. <i>Cancer Control</i> , 2002 , 9, 513-23	2.2	6
29	Mediastinal lymphadenopathy in a patient with breast cancer. <i>Lancet Oncology</i> , 2002 , 3, 174	21.7	2

28	Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. <i>Anticancer Research</i> , 2002 , 22, 3057-9	2.3	32
27	Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. <i>Lung Cancer</i> , 2001 , 31, 267-70	5.9	17
26	Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms. <i>Annals of Oncology</i> , 2001 , 12, 724-5	10.3	11
25	Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. <i>Oncology</i> , 2001 , 60, 308-12	3.6	17
24	Gemcitabine-induced systemic capillary leak syndrome. <i>Annals of Oncology</i> , 2001 , 12, 1651-2	10.3	34
23	Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2001 , 12, 1553-9	10.3	29
22	Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. <i>Anticancer Research</i> , 2001 , 21, 585-8	2.3	15
21	Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. <i>Anticancer Research</i> , 2001 , 21, 3015-20	2.3	2
20	GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. <i>Anticancer Research</i> , 2001 , 21, 3461-9	2.3	2
19	Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. <i>Anticancer Research</i> , 2001 , 21, 4135-9	2.3	7
18	Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. <i>Annals of Oncology</i> , 2000 , 11, 1057-9	10.3	80
17	ACUTE VULVAR VESTIBULITIS OCCURRING DURING CHEMOTHERAPY WITH CRYPTOPHYCIN ANALOGUE LY355703. <i>Obstetrics and Gynecology</i> , 2000 , 95, 1030	4.9	4
16	Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2000 , 11, 821-7	10.3	25
15	Ifosfamide in the elderly: clinical considerations for a better drug management. <i>Critical Reviews in Oncology/Hematology</i> , 2000 , 33, 129-35	7	9
14	Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?. <i>Annals of Oncology</i> , 2000 , 11, 117-8	10.3	8
13	Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LYy355703. <i>Obstetrics and Gynecology</i> , 2000 , 95, 1030	4.9	1
12	Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2000 , 6, 2393-400	12.9	14
11	Evaluation of polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral cells by an immunohistochemical assay. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 1999 , 8, 91-6	4	9

10	Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma. <i>Anticancer Research</i> , 1999 , 19, 4571-6	2.3	3
9	P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer. <i>Breast Journal</i> , 1998 , 4, 270-6	1.2	0
8	4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study. <i>Carcinogenesis</i> , 1998 , 19, 353-7	4.6	17
7	Immunohistochemical analysis of p53 protein in transplant recipients with Kaposi's sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997 , 123, 240-2	4.9	8
6	Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts in oral mucosal cells of smokers and nonsmokers. <i>Anticancer Research</i> , 1997 , 17, 2827-30	2.3	16
5	Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. <i>European Journal of Cancer</i> , 1996 , 32A, 802-6	7.5	49
4	Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. <i>Diseases of the Colon and Rectum</i> , 1996 , 39, 1238-44	3.1	34
3	Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. <i>Carcinogenesis</i> , 1996 , 17, 911-6	4.6	52
2	Emerging treatment landscape of non-muscle invasive bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 1-18	5.4	0
1	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. <i>JAMA Oncology</i> ,	13.4	2